

# J Genesca

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2793063/publications.pdf>

Version: 2024-02-01

141  
papers

10,158  
citations

36299

51  
h-index

36025

97  
g-index

158  
all docs

158  
docs citations

158  
times ranked

7230  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. <i>Journal of Virology</i> , 1992, 66, 3225-3229.	3.4	858
2	HEPATITIS C VIRUS ANTIBODIES AMONG RISK GROUPS IN SPAIN. <i>Lancet, The</i> , 1989, 334, 294-297.	13.7	833
3	β-blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2019, 393, 1597-1608.	13.7	375
4	A MELD-Based Model to Determine Risk of Mortality Among Patients With Acute Variceal Bleeding. <i>Gastroenterology</i> , 2014, 146, 412-419.e3.	1.3	285
5	Cardiac alterations in cirrhosis: reversibility after liver transplantation. <i>Journal of Hepatology</i> , 2005, 42, 68-74.	3.7	281
6	High Prevalence of Hepatitis C Virus Infection in Diabetic Patients. <i>Diabetes Care</i> , 1996, 19, 998-1000.	8.6	253
7	High Rate of Infectivity and Liver Disease in Blood Donors with Antibodies to Hepatitis C Virus. <i>Annals of Internal Medicine</i> , 1991, 115, 443-449.	3.9	251
8	Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study. <i>Hepatology</i> , 2016, 64, 2173-2184.	7.3	251
9	Addition of Simvastatin to Standard Therapy for the Prevention of Variceal Rebleeding Does Not Reduce Rebleeding but Increases Survival in Patients With Cirrhosis. <i>Gastroenterology</i> , 2016, 150, 1160-1170.e3.	1.3	232
10	Effects of an intensive lifestyle intervention program on portal hypertension in patients with cirrhosis and obesity: The SportDiet study. <i>Hepatology</i> , 2017, 65, 1293-1305.	7.3	225
11	Expanding the Baveno VI criteria for the screening of varices in patients with compensated advanced chronic liver disease. <i>Hepatology</i> , 2017, 66, 1980-1988.	7.3	223
12	Blood metabolomics uncovers inflammation-associated mitochondrial dysfunction as a potential mechanism underlying ACLF. <i>Journal of Hepatology</i> , 2020, 72, 688-701.	3.7	223
13	High mortality rates for SARS-CoV-2 infection in patients with pre-existing chronic liver disease and cirrhosis: Preliminary results from an international registry. <i>Journal of Hepatology</i> , 2020, 73, 705-708.	3.7	213
14	High Prevalence of Glucose Abnormalities in Patients With Hepatitis C Virus Infection: A multivariate analysis considering the liver injury. <i>Diabetes Care</i> , 2004, 27, 1171-1175.	8.6	183
15	Antithrombotic treatment with direct-acting oral anticoagulants in patients with splanchnic vein thrombosis and cirrhosis. <i>Liver International</i> , 2017, 37, 694-699.	3.9	178
16	Association Between Portosystemic Shunts and Increased Complications and Mortality in Patients With Cirrhosis. <i>Gastroenterology</i> , 2018, 154, 1694-1705.e4.	1.3	162
17	Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: A double-blind RCT. <i>Hepatology</i> , 2003, 37, 1260-1266.	7.3	149
18	Preemptive TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. <i>Hepatology</i> , 2019, 69, 282-293.	7.3	144

#	ARTICLE	IF	CITATIONS
19	Development of hyperdynamic circulation and response to $\beta$ -blockers in compensated cirrhosis with portal hypertension. <i>Hepatology</i> , 2016, 63, 197-206.	7.3	143
20	Predicting Early Mortality After Acute Variceal Hemorrhage Based on Classification and Regression Tree Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2009, 7, 1347-1354.	4.4	137
21	Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. <i>Journal of Hepatology</i> , 2020, 72, 472-480.	3.7	130
22	Detection of early portal hypertension with routine data and liver stiffness in patients with asymptomatic liver disease: A prospective study. <i>Journal of Hepatology</i> , 2014, 60, 561-569.	3.7	124
23	Sustained Virological Response Correlates With Reduction in the Incidence of Glucose Abnormalities in Patients With Chronic Hepatitis C Virus Infection. <i>Diabetes Care</i> , 2006, 29, 2462-2466.	8.6	118
24	Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. <i>Journal of Hepatology</i> , 2020, 73, 1082-1091.	3.7	112
25	Effectiveness of Combined Pharmacologic and Ligation Therapy in High-Risk Patients With Acute Esophageal Variceal Bleeding. <i>American Journal of Gastroenterology</i> , 2011, 106, 1787-1795.	0.4	108
26	Interferon- $\alpha$ in acute posttransfusion hepatitis C: A randomized, controlled trial. <i>Hepatology</i> , 1992, 15, 767-769.	7.3	107
27	Impact of anticoagulation on upper gastrointestinal bleeding in cirrhosis. A retrospective multicenter study. <i>Hepatology</i> , 2015, 62, 575-583.	7.3	105
28	Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. <i>American Journal of Gastroenterology</i> , 2021, 116, 723-732.	0.4	105
29	Interleukin-6, Nitric Oxide, and the Clinical and Hemodynamic Alterations of Patients With Liver Cirrhosis. <i>American Journal of Gastroenterology</i> , 1999, 94, 169-177.	0.4	103
30	Isosorbide Mononitrate in the Prevention of First Variceal Bleed in Patients Who Cannot Receive $\beta$ -blockers. <i>Gastroenterology</i> , 2001, 121, 908-914.	1.3	103
31	Total area of spontaneous portosystemic shunts independently predicts hepatic encephalopathy and mortality in liver cirrhosis. <i>Journal of Hepatology</i> , 2020, 72, 1140-1150.	3.7	97
32	Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. <i>Gastroenterology</i> , 2021, 160, 193-205.e10.	1.3	97
33	Congenital Extrahepatic Portosystemic Shunts (Abernethy Malformation): An International Observational Study. <i>Hepatology</i> , 2020, 71, 658-669.	7.3	95
34	Isosorbide mononitrate in the prevention of first variceal bleed in patients who cannot receive $\beta$ -blockers. <i>Gastroenterology</i> , 2001, 121, 908-914.	1.3	94
35	Physiopathology of splanchnic vasodilation in portal hypertension. <i>World Journal of Hepatology</i> , 2010, 2, 208.	2.0	94
36	WHAT DO WESTERN BLOT INDETERMINATE PATTERNS FOR HUMAN IMMUNODEFICIENCY VIRUS MEAN IN EIA-NEGATIVE BLOOD DONORS?. <i>Lancet</i> , The, 1989, 334, 1023-1025.	13.7	85

#	ARTICLE	IF	CITATIONS
37	Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. <i>Hepatology</i> , 2018, 67, 1485-1498.	7.3	85
38	ROLE OF DOPPLER ECHOCARDIOGRAPHY IN THE ASSESSMENT OF PORTOPULMONARY HYPERTENSION IN LIVER TRANSPLANTATION CANDIDATES <sup>1</sup> . <i>Transplantation</i> , 2001, 71, 572-574.	1.0	84
39	Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. <i>Gastroenterology</i> , 2019, 157, 705-719.e18.	1.3	82
40	Proinflammatory Cytokines, Insulin Resistance, and Insulin Secretion in Chronic Hepatitis C patients: A case-control study. <i>Diabetes Care</i> , 2006, 29, 1096-1101.	8.6	81
41	Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 313-327.e6.	4.4	74
42	Documento de consenso. Manejo de la enfermedad hepática grasa no alcohólica (EHGNA). Guía de práctica clínica. <i>Gastroenterología Y Hepatología</i> , 2018, 41, 328-349.	0.5	71
43	Blood-Borne Non-A, Non-B Hepatitis: Hepatitis C. <i>Seminars in Liver Disease</i> , 1991, 11, 147-164.	3.6	67
44	Increased tumour necrosis factor $\alpha$ production in mesenteric lymph nodes of cirrhotic patients with ascites. <i>Gut</i> , 2003, 52, 1054-1059.	12.1	67
45	Non-Invasive Prediction of High-Risk Varices in Patients with Primary Biliary Cholangitis and Primary Sclerosing Cholangitis. <i>American Journal of Gastroenterology</i> , 2019, 114, 446-452.	0.4	65
46	Structure of replicating hepatitis C virus (HCV) quasispecies in the liver may not be reflected by analysis of circulating HCV virions. <i>Journal of Virology</i> , 1997, 71, 1732-1734.	3.4	64
47	Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis. <i>Journal of Hepatology</i> , 2022, 77, 1014-1025.	3.7	64
48	Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*Z vs Pi*MZ) Tj ETQq0,0 0 rgBT /Overlock	1.3	63
49	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , 2022, 76, 812-821.	3.7	59
50	Glucose Abnormalities in Patients with Hepatitis C Virus Infection: Epidemiology and pathogenesis. <i>Diabetes Care</i> , 2006, 29, 1140-1149.	8.6	55
51	Hemodynamic responseâ€“guided therapy for prevention of variceal rebleeding: An uncontrolled pilot study. <i>Hepatology</i> , 2006, 44, 806-812.	7.3	54
52	Multicenter External Validation of Risk Stratification Criteria for Patients With Variceal Bleeding. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 132-139.e8.	4.4	54
53	Elastography methods for the non-invasive assessment of portal hypertension. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 155-164.	3.0	54
54	Diabetes Is the Main Factor Accounting for the High Ferritin Levels Detected in Chronic Hepatitis C Virus Infection. <i>Diabetes Care</i> , 2004, 27, 2669-2675.	8.6	53

#	ARTICLE	IF	CITATIONS
55	Acute esophageal variceal bleeding: Current strategies and new perspectives. <i>World Journal of Hepatology</i> , 2010, 2, 261.	2.0	51
56	Islet cell and thyroid antibody prevalence in patients with hepatitis C virus infection: Effect of treatment with interferon. <i>Translational Research</i> , 2001, 137, 38-42.	2.3	48
57	Rebleeding prophylaxis improves outcomes in patients with hepatocellular carcinoma. A multicenter case-control study. <i>Hepatology</i> , 2013, 58, 2079-2088.	7.3	48
58	Adrenomedullin, a vasodilator peptide implicated in hemodynamic alterations of liver cirrhosis: relationship to nitric oxide. <i>Digestive Diseases and Sciences</i> , 1999, 44, 372-376.	2.3	47
59	Rapid liver and spleen stiffness improvement in compensated advanced chronic liver disease patients treated with oral antivirals. <i>Therapeutic Advances in Gastroenterology</i> , 2017, 10, 619-629.	3.2	45
60	Clinical Correlation and Genetic Polymorphism of the Human Immunodeficiency Virus Proviral DNA Obtained after Polymerase Chain Reaction Amplification. <i>Journal of Infectious Diseases</i> , 1990, 162, 1025-1030.	4.0	44
61	Validating the Baveno VI recommendations for screening varices. <i>Journal of Hepatology</i> , 2017, 66, 459-460.	3.7	43
62	Hepatitis D virus RNA in acute delta infection: Serological profile and correlation with other markers of hepatitis D virus infection. <i>Hepatology</i> , 1988, 8, 1125-1129.	7.3	42
63	Glucose Abnormalities Are an Independent Risk Factor for Nonresponse to Antiviral Treatment in Chronic Hepatitis C. <i>American Journal of Gastroenterology</i> , 2007, 102, 2189-2195.	0.4	40
64	Hepatitis b virus replication in acute hepatitis B, acute hepatitis B virus-hepatitis delta virus coinfection and acute hepatitis delta superinfection. <i>Hepatology</i> , 1987, 7, 569-572.	7.3	38
65	Bacterial infections adversely influence the risk of decompensation and survival in compensated cirrhosis. <i>Journal of Hepatology</i> , 2021, 75, 589-599.	3.7	36
66	Restoration of liver sinusoidal cell phenotypes by statins improves portal hypertension and histology in rats with NASH. <i>Scientific Reports</i> , 2019, 9, 20183.	3.3	35
67	A Nitric Oxide-Donating Statin Decreases Portal Pressure with a Better Toxicity Profile than Conventional Statins in Cirrhotic Rats. <i>Scientific Reports</i> , 2017, 7, 40461.	3.3	33
68	Immunoprophylaxis of perinatal transmission of the hepatitis B virus: Efficacy of hepatitis B immune globulin and hepatitis B vaccine in a low-prevalence area. <i>Journal of Medical Virology</i> , 1986, 18, 381-391.	5.0	30
69	Hepatitis C virus infection in renal transplant recipients: epidemiology, clinical impact, serological confirmation and viral replication. <i>Journal of Hepatology</i> , 1995, 22, 272-277.	3.7	30
70	Long-term follow-up of hemodynamic responders to pharmacological therapy after variceal bleeding. <i>Hepatology</i> , 2012, 56, 706-714.	7.3	30
71	Spontaneous portosystemic shunts in liver cirrhosis: new approaches to an old problem. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482096128.	3.2	30
72	Role of immunosuppression in the development of quinolone-resistant <i>Escherichia coli</i> spontaneous bacterial peritonitis and in the mortality of <i>E. coli</i> spontaneous bacterial peritonitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2003, 17, 695-701.	3.7	29

#	ARTICLE	IF	CITATIONS
73	Down-regulation of genes related to the adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension. <i>Journal of Hepatology</i> , 2008, 49, 43-51.	3.7	28
74	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. <i>Gut</i> , 2022, 71, 415-423.	12.1	28
75	Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. <i>Journal of Hepatology</i> , 2021, 75, 342-350.	3.7	28
76	Impact of ornithine phenylacetate (OCR-002) in lowering plasma ammonia after upper gastrointestinal bleeding in cirrhotic patients. <i>Therapeutic Advances in Gastroenterology</i> , 2016, 9, 823-835.	3.2	25
77	Diabetic retinopathy as an independent predictor of subclinical cardiovascular disease: baseline results of the PRECISED study. <i>BMJ Open Diabetes Research and Care</i> , 2019, 7, e000845.	2.8	24
78	Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: Final report of a prospective trial. <i>Hepatology</i> , 1995, 22, 439-445.	7.3	23
79	Atrophy of mesenteric sympathetic innervation may contribute to splanchnic vasodilation in rat portal hypertension. <i>Liver International</i> , 2010, 30, 593-602.	3.9	23
80	High doses of $\beta$ -blockers and alcohol abstinence improve long-term rebleeding and mortality in cirrhotic patients after an acute variceal bleeding. <i>Liver International</i> , 2010, 30, 1123-1130.	3.9	23
81	Enfermedades vasculares del h�gado. Gu�as Cl�nicas de la Sociedad Catalana de Digestolog�a y de la Asociaci�n Espa�ola para el Estudio del H�gado. <i>Gastroenterolog�a Y Hepatolog�a</i> , 2017, 40, 538-580.	0.5	20
82	Effect of rifaximin on infections, acute-on-chronic liver failure and mortality in alcoholic hepatitis: A pilot study (RIFA�AH). <i>Liver International</i> , 2022, 42, 1109-1120.	3.9	20
83	Validation of Automated Blood Cell Counters for the Diagnosis of Spontaneous Bacterial Peritonitis. <i>American Journal of Gastroenterology</i> , 2004, 99, 1400-1400.	0.4	19
84	Role of host and bacterial virulence factors in Escherichia coli spontaneous bacterial peritonitis. <i>European Journal of Gastroenterology and Hepatology</i> , 2008, 20, 924-929.	1.6	19
85	Cerebellar neurodegeneration in a new rat model of episodic hepatic encephalopathy. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2017, 37, 927-937.	4.3	18
86	Clinical and serological outcome of acute delta infection. <i>Journal of Hepatology</i> , 1987, 5, 59-64.	3.7	17
87	Hepatitis C virus markers in patients with acute post-transfusion hepatitis treated with interferon alfa-2b. <i>Gut</i> , 1993, 34, S62-S63.	12.1	16
88	Efficacy of screening donors for antibodies to the hepatitis C virus to prevent transfusion-associated hepatitis: Final report of a prospective trial*1. <i>Hepatology</i> , 1995, 22, 439-445.	7.3	16
89	Predicting 6-week mortality after acute variceal bleeding: role of classification and regression tree analysis. <i>Annals of Hepatology</i> , 2009, 8, 308-315.	1.5	15
90	Basal values and changes of liver stiffness predict the risk of disease progression in compensated advanced chronic liver disease. <i>Digestive and Liver Disease</i> , 2016, 48, 1214-1219.	0.9	15

#	ARTICLE	IF	CITATIONS
91	Blockage of the afferent sensitive pathway prevents sympathetic atrophy and hemodynamic alterations in rat portal hypertension. <i>Liver International</i> , 2012, 32, 1295-1305.	3.9	14
92	Hepatitis C: molecular biology, pathogenesis, epidemiology, clinical features, and prevention. <i>Progress in Liver Diseases</i> , 1992, 10, 253-82.	0.3	14
93	Simvastatin-loaded polymeric micelles are more effective and less toxic than conventional statins in a pre-clinical model of advanced chronic liver disease. <i>Nanomedicine: Nanotechnology, Biology, and Medicine</i> , 2020, 29, 102267.	3.3	12
94	Enfermedad hepática por alcohol. Guías de práctica clínica. Documento de consenso auspiciado por la AEEH. <i>Gastroenterología Y Hepatología</i> , 2019, 42, 657-676.	0.5	12
95	Droxidopa, an oral norepinephrine precursor, improves hemodynamic and renal alterations of portal hypertensive rats. <i>Hepatology</i> , 2012, 56, 1849-1860.	7.3	11
96	Alcohol consumption and risk of infection after a variceal bleeding in low-risk patients. <i>Liver International</i> , 2016, 36, 994-1001.	3.9	11
97	Identifying Compensated Advanced Chronic Liver Disease: When (Not) to Start Screening for Varices and Clinically Significant Portal Hypertension. , 2016, , 39-49.		11
98	High HCV subtype heterogeneity in a chronically infected general population revealed by high-resolution hepatitis C virus subtyping. <i>Clinical Microbiology and Infection</i> , 2017, 23, 775.e1-775.e6.	6.0	11
99	Covert hepatic encephalopathy and spontaneous portosystemic shunts increase the risk of developing overt hepatic encephalopathy. <i>Liver International</i> , 2020, 40, 3093-3102.	3.9	11
100	Nitric oxide may contribute to nocturnal hemodynamic changes in cirrhotic patients. <i>American Journal of Gastroenterology</i> , 2000, 95, 1539-1544.	0.4	10
101	Vascular diseases of the liver. Clinical Guidelines from the Catalan Society of Digestology and the Spanish Association for the Study of the Liver. <i>Gastroenterología Y Hepatología (English Edition)</i> , 2017, 40, 538-580.	0.1	10
102	Utility of Transient Elastography for the Screening of Liver Disease in Patients with Alpha1-Antitrypsin Deficiency. <i>Journal of Clinical Medicine</i> , 2021, 10, 1724.	2.4	10
103	Duration of the acute hepatic encephalopathy episode determines survival in cirrhotic patients. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 1756283X1774341.	3.2	9
104	Synergic effect of atorvastatin and ambrisentan on sinusoidal and hemodynamic alterations in a rat model of NASH. <i>DMM Disease Models and Mechanisms</i> , 2021, 14, .	2.4	9
105	Spontaneous bacterial peritonitis caused by quinolone-resistant <i>Escherichia coli</i> : could steroid therapy play a role?. <i>European Journal of Gastroenterology and Hepatology</i> , 2002, 14, 81-83.	1.6	8
106	Inhibition of Neuronal Apoptosis and Axonal Regression Ameliorates Sympathetic Atrophy and Hemodynamic Alterations in Portal Hypertensive Rats. <i>PLoS ONE</i> , 2014, 9, e84374.	2.5	8
107	WHEN SHOULD AT-RISK INFANTS BE BOOSTED WITH HEPATITIS B VACCINE?. <i>Lancet, The</i> , 1987, 329, 49.	13.7	7
108	The role of liver steatosis as measured with transient elastography and transaminases on hard clinical outcomes in patients with COVID-19. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110165.	3.2	7



#	ARTICLE	IF	CITATIONS
109	Vascular endothelial growth factor levels in liver cirrhosis. <i>Digestive Diseases and Sciences</i> , 1999, 44, 1261-1262.	2.3	6
110	Adding banding ligation is effective as rescue therapy to prevent variceal rebleeding in haemodynamic non-responders to pharmacological therapy. <i>Digestive and Liver Disease</i> , 2012, 44, 55-60.	0.9	6
111	Should prophylactic embolization of spontaneous portosystemic shunts be routinely performed during transjugular intrahepatic portosystemic shunt placement?. <i>Digestive and Liver Disease</i> , 2018, 50, 1324-1326.	0.9	6
112	Reply to: "Definition of SPSS: we need to speak the same language". <i>Journal of Hepatology</i> , 2020, 73, 464-465.	3.7	6
113	Evaluation of anti-HCV positive blood donors identified during routine screening. <i>Archives of Virology Supplementum</i> , 1992, 4, 244-246.	3.0	6
114	Reply to "Points to be considered when using transient elastography for diagnosis of portal hypertension according to the Baveno VI consensus". <i>Journal of Hepatology</i> , 2015, 63, 1049-1050.	3.7	5
115	The renal effects of droxidopa are maintained in propranolol treated cirrhotic rats. <i>Liver International</i> , 2015, 35, 326-334.	3.9	5
116	Diagnostic and Prognostic Markers in Liver Cirrhosis. <i>Disease Markers</i> , 2011, 31, 119-120.	1.3	5
117	Effects of Albumin on Survival after a Hepatic Encephalopathy Episode: Randomized Double-Blind Trial and Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021, 10, 4885.	2.4	5
118	Disappearance of serum hepatitis B virus DNA by polymerase chain reaction after adenine arabinoside 5' monophosphate therapy in chronic hepatitis B. <i>Liver</i> , 1993, 13, 136-140.	0.1	4
119	$\beta_1$ and $\beta_2$ adrenergic agonists on cirrhotic patients with refractory ascites. <i>Liver International</i> , 2016, 36, 177-180.	3.9	4
120	Trends in Diagnosis of Alpha-1 Antitrypsin Deficiency Between 2015 and 2019 in a Reference Laboratory. <i>International Journal of COPD</i> , 2020, Volume 15, 2421-2431.	2.3	4
121	A Diet Combining High Fat and Glucose-Fructose Syrup Induces Obesity, Non-Alcoholic Steatohepatitis and Portal Hypertension in a New Animal Model. <i>Journal of Hepatology</i> , 2016, 64, S452-S453.	3.7	3
122	Ruling in and ruling out with elastography in compensated advanced chronic liver disease. <i>Gut</i> , 2017, 66, 197-198.	12.1	3
123	Beyond Baveno VI: How far are we?. <i>Digestive and Liver Disease</i> , 2019, 51, 1141-1143.	0.9	3
124	Serum miR-181b-5p predicts ascites onset in patients with compensated cirrhosis. <i>JHEP Reports</i> , 2021, 3, 100368.	4.9	3
125	Comparison of four different antigen-capture assays for the detection of human immunodeficiency virus antigen (HIV-Ag). <i>Journal of Acquired Immune Deficiency Syndromes</i> , 1989, 2, 170-77.	1.0	3
126	Prognostic Evaluation of Patients with Acute Variceal Bleeding. <i>Disease Markers</i> , 2011, 31, 155-164.	1.3	2



#	ARTICLE	IF	CITATIONS
127	Steatosis as main determinant of portal hypertension through a restriction of hepatic sinusoidal area in a dietary rat nash model. <i>Liver International</i> , 2020, 40, 2732-2743.	3.9	2
128	Do we need to re-define the Baveno VI elastography criteria for compensated advanced chronic liver disease (cACLD)?. <i>Journal of Hepatology</i> , 2021, 75, 750-752.	3.7	2
129	A Nine-Strain Bacterial Consortium Improves Portal Hypertension and Insulin Signaling and Delays NAFLD Progression In Vivo. <i>Biomedicines</i> , 2022, 10, 1191.	3.2	2
130	Familial amyloidosis in a large Spanish kindred resulting from a D38V mutation in the transthyretin gene. <i>European Journal of Clinical Investigation</i> , 2007, 37, 673-678.	3.4	1
131	Evaluation and treatment of the critically ill cirrhotic patient. <i>Gastroenterology &amp; Hepatology (English Edition)</i> , 2016, 39, 607-626.	0.1	1
132	Risk Stratification in Acute Variceal Bleeding: Child-Pugh Versus Model for End-stage Liver Disease. <i>Journal of Clinical Gastroenterology</i> , 2019, 53, 549-549.	2.2	1
133	Lack of HIV transmission after hepatitis B immunoprophylaxis. <i>Infection</i> , 1987, 15, 366-366.	4.7	0
134	Diabetes Is the Main Factor Accounting for the High Ferritin Levels Detected in Chronic Hepatitis C Virus Infection: Response to Sebastiani et al.. <i>Diabetes Care</i> , 2005, 28, 1838-1839.	8.6	0
135	Response to Heish et al.. <i>American Journal of Gastroenterology</i> , 2008, 103, 488-488.	0.4	0
136	Reply. <i>Hepatology</i> , 2014, 60, 1795-1796.	7.3	0
137	Risk Stratification with Noninvasive Tools in Patients with Compensated Cirrhosis. <i>Current Hepatology Reports</i> , 2017, 16, 228-236.	0.9	0
138	Reply. <i>Gastroenterology</i> , 2018, 155, 1650-1651.	1.3	0
139	Reply to: "Evaluating the role of transient elastography post chronic hepatitis C treatment to predict hepatocellular carcinoma". <i>Journal of Hepatology</i> , 2020, 73, 1289-1290.	3.7	0
140	Reply to: "Hepatocellular carcinoma surveillance after hepatitis C virus eradication: Is liver stiffness measurement more useful than laboratory fibrosis markers?" and "External validation of noninvasive predictors of hepatocellular carcinoma in patients with HCV advanced chronic liver disease after oral antivirals". <i>Journal of Hepatology</i> , 2020, 73, 472-473.	3.7	0
141	Prediction of hepatocellular carcinoma after sustained virologic response in patients with compensated advanced chronic liver disease. , 2021, 59, ,		0